You are here: Industry Insights > InnoCare

News List

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2023 Hybrid Congress PharmaSources
June 12, 2023
On June 12, 2023,Data of InnoCare’s robust pipelines were presented at the European Hematology Association 2023 Hybrid Congress.
InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL PharmaSources
April 20, 2023
April 20, 2023，InnoCare Pharma announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration in the treatment of patients with relapsed/refractory marginal zone lymphoma .
Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting PharmaSources
April 18, 2023
April 18, 2023，Data of InnoCare’s robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
InnoCare Announces First Subject Dosed in Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China PharmaSources
April 04, 2023
April 4, 2023，InnoCare Pharma announced today that the first subject has been dosed in clinical trial of the Company’s novel targeted protein degrader ICP-490 in China.
Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology PharmaSources
February 07, 2023
American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) patients.
InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI PharmaSources
January 06, 2023
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China PharmaSources.com
December 20, 2022
InnoCare Pharma announced today that the Company has received approval from the Center for Drug Evaluation (CDE) to conduct a single-arm, open-label, multi-cohort phase II clinical trial.
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore PharmaSources.com
November 22, 2022
InnoCare Pharma that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL).
InnoCare Releases 2022 Third Quarter Results: Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales PharmaSources.com
November 16, 2022
InnoCare Pharma announced 2022 third quarter results and latest corporate development.
InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA PharmaSources.com
September 06, 2022
So far, no BTK inhibitor has ever been approved for treating patients with R/R MZL in China, and hope that orelabrutinib can fill the gap in this therapeutic area.

Previous page 1 2 3 4 5 6 7 Next page